Evidence map›Paper›PMID 38250731›Full record

ArticlePeerJ2024

Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma.

Maoqing Jiang, Xiuyu Guo, Ping Chen, Xiaohui Zhang, Qiaoling Gao, Jingfeng Zhang, Jianjun Zheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maoqing JiangDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.ORCID 0000-0002-8734-2067
Xiuyu GuoDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Ping ChenDepartment of Nephrology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Xiaohui ZhangDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Qiaoling GaoDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Jingfeng ZhangDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Jianjun ZhengDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Ningbo No. 2 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The objective of this study was to investigate the prognostic significance of total metabolic tumor volume (TMTV) derived from baseline Methods: We performed a retrospective analysis on 141 patients with LUAD (74 males, 67 females, median age 67 (range 34-86)) who underwent Results: The EGFR mutant patients ( Conclusion: Our study demonstrates that the integration of TMTV on baseline

Indexed as

Adenocarcinoma of LungLung NeoplasmsAdultAgedAged, 80 and overErbB ReceptorsFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMutationPositron Emission Tomography Computed TomographyPrognosisRetrospective StudiesTumor BurdenEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F1818F-2-fluoro-2-deoxyglucoseComputed tomographyEpidermal growth factor receptorLung adenocarcinomaMetabolic tumor volumePositron emission tomography

Identifiers

PMID38250731
PMCPMC10799611
OpenAlexW4390950473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.